Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10940
Title: Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
Authors: Seeman, Ego;Boonen, Steven;Borgström, Frederik;Vellas, Bruno;Aquino, Jean-Pierre;Semler, Jutta;Benhamou, Claude-Laurent;Kaufman, Jean-Marc;Reginster, Jean-Yves
Affiliation: Austin Health, University of Melbourne, Melbourne, Australia. egos@unimelb.edu.au
Issue Date: 21-Dec-2009
Citation: Bone 2009; 46(4): 1038-42
Abstract: Longevity has resulted in a greater proportion of the population entering a time of life when increasing bone fragility and falls predispose to fractures, particularly nonvertebral fractures. Women over 80 years of age constitute 10% of the population but contribute 30% of all fractures and 60% of all nonvertebral fractures. Despite this, few studies have examined antifracture efficacy of treatments in this high-risk group and none has provided evidence for benefits beyond 3 years.To determine whether strontium ranelate reduces the risk of vertebral and nonvertebral fractures during 5 years, we analyzed a subgroup of 1489 female patients over 80 years of age (mean 83.5+/-3.0 years) with osteoporosis from the SOTI (spinal osteoporosis therapeutic intervention) and TROPOS (treatment of peripheral osteoporosis) studies randomized to strontium ranelate 2 g/d or placebo. All received a supplement of calcium plus vitamin D.By intention to treat, vertebral fracture risk was reduced by 31% (relative risk, RR=0.69; 95% confidence interval, CI 0.52-0.92), nonvertebral fracture risk by 27% (RR=0.73; 95% CI 0.57-0.95), major nonvertebral fracture risk by 33% (RR=0.67; 95% CI 0.50-0.89) and hip fracture risk by 24% (RR=0.76; 95% CI 0.50-1.15, not significant). Treatment was cost-saving as it decreased cost and increased QALYs and life-years.Strontium ranelate safely produced a significant reduction in vertebral and nonvertebral fracture risk during 5 years in postmenopausal women over 80 years of age and was cost saving.
Internal ID Number: 20026265
URI: http://ahro.austin.org.au/austinjspui/handle/1/10940
DOI: 10.1016/j.bone.2009.12.006
URL: http://www.ncbi.nlm.nih.gov/pubmed/20026265
Type: Journal Article
Subjects: Aged, 80 and over
Bone Density.drug effects
Bone Density Conservation Agents.therapeutic use
Bone and Bones.drug effects
Calcium, Dietary.therapeutic use
Female
Hip Fractures.prevention & control
Humans
Intention to Treat Analysis
Organometallic Compounds.therapeutic use
Osteoporosis, Postmenopausal.drug therapy
Quality of Life
Spinal Fractures.prevention & control
Thiophenes.therapeutic use
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.